Login to Your Account



Symphogen Inks $632M Deal with Merck for Cancer Drug

By Nuala Moran
Staff Writer

Wednesday, September 12, 2012

LONDON – Symphogen A/S has handed Merck KGaA worldwide exclusive rights to its Phase II cancer antibody product, Sym004, in a deal with a potential value of €500 million (US$631.6 million).

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription